MINNEAPOLIS, December 03, 2024--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic ...
The ReoPro Retavase Reperfusion of Stroke Safety Study (ROSIE) is an NIH-sponsored Phase II trial evaluating intravenous reteplase in combination with abciximab for the treatment of patients with ...
Hypoxic-ischemic encephalopathy (HIE) is one of the leading causes of newborn mortality and morbidity worldwide, and lowering the baby’s body temperature—called therapeutic hypothermia—is often used ...
Acute limb ischemia occurs due to a sudden decrease in the blood flow to a limb, resulting in a potential threat to the viability of the extremity. Unfortunately, the threat is not only to the ...